Docket No.: 60677(49163)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Maurice S. Swanson

Application No.: 10/591,883 | Confirmation No.: 3251

Filed: December 10, 2007 | Art Unit: 1632

For: METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASES ASSOCIATED WITH ABERRANT MICROSATTELITE EXPANSION | Examiner: Ton, THAIAN N

RESPONSE TO NON-FINAL OFFICE ACTION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Amendment is being filed in response to the Non-Final Office Action mailed from the U.S. Patent and Trademark Office on May 15, 2009 in the above-identified application.

Amendments to the Specification being on page 2 of this paper.

Amendments to the Claims are shown in the "Listing of the Claims" which begins on page 3 of this paper.

Remarks begin on page 6 of this paper.

Amendments to the Specification:

On page 1, please replace the paragraph beginning at line 18 with the following:

This work was supported in part by a grant from the National Institutes of Health (U54-NS48843). The United States Government ~~may have~~ has certain rights to the invention

On page 33, please replace the paragraph beginning at line 20 with the following:

SiRNA construct design and transfection: two custom siRNA duplexes were designed for RNAi against human MBNL1 using the Dharmacon siDESIGN program available on the world wide web at dharmacon.com, ~~(www.dharmacon.com (http://www.dharmacon.com/))~~ and were synthesized by Dharmacon. The sequences are as follows: THH31 mRNA target (AA-N19 format 5' → 3') AACAGACAGACUUGAGGUAUG (SEQ ID NO: 35), THH2 mRNA target (AA-N19 format 5' →3') AACACGGAAUGUAAAUUUGCA (SEQ ID NO: 36), GFP siRNA duplex (Dharmacon, Lafayette, Colo. cat. no. D-001300-01-20). 300 000 HeLa cells were plated in 2 ml of antibiotic-free growth media (DMEM supplemented with 10% FBS) per well in a six-well plate. HeLa cells were chosen because they express MBNL1 (Miller J W, Urbinati C R, Teng-Umnuay P, Stenberg M G, Byrne B J, Thornton C A, Swanson M S (2000), EMBO J 19: 4439-4448) and are amenable to siRNA-mediated depletion (Elbashir S M, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001), Nature 411: 494-498).